[go: up one dir, main page]

PT1395553E - Derivados de pirrolidina como inibidores do factor xa - Google Patents

Derivados de pirrolidina como inibidores do factor xa

Info

Publication number
PT1395553E
PT1395553E PT02738368T PT02738368T PT1395553E PT 1395553 E PT1395553 E PT 1395553E PT 02738368 T PT02738368 T PT 02738368T PT 02738368 T PT02738368 T PT 02738368T PT 1395553 E PT1395553 E PT 1395553E
Authority
PT
Portugal
Prior art keywords
inhibitors
factor
pirrolidine
derivatives
pirrolidine derivatives
Prior art date
Application number
PT02738368T
Other languages
English (en)
Inventor
Chuen Chan
Nigel Stephen Watson
Robert John Young
Caroline Whitworth
Gita Punjabhai Shah
Hamblin Julie Nicole
Kelly Henry Anderson
King Nigel Paul
Mason Andrew Mcmurtrie
Patel Vipulkumar Kantibhai
Senger Stefan
Weston Helen Elisabeth
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PT1395553E publication Critical patent/PT1395553E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT02738368T 2001-06-08 2002-06-06 Derivados de pirrolidina como inibidores do factor xa PT1395553E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0114005.2A GB0114005D0 (en) 2001-06-08 2001-06-08 Chemical compounds

Publications (1)

Publication Number Publication Date
PT1395553E true PT1395553E (pt) 2005-06-30

Family

ID=9916209

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02738368T PT1395553E (pt) 2001-06-08 2002-06-06 Derivados de pirrolidina como inibidores do factor xa

Country Status (29)

Country Link
US (4) US7186717B2 (pt)
EP (1) EP1395553B1 (pt)
JP (1) JP4242274B2 (pt)
KR (1) KR100877245B1 (pt)
CN (1) CN1256324C (pt)
AR (1) AR036086A1 (pt)
AT (1) ATE289294T1 (pt)
AU (1) AU2002311451B2 (pt)
BR (1) BR0210207A (pt)
CA (1) CA2449629A1 (pt)
CO (1) CO5540285A2 (pt)
CZ (1) CZ20033325A3 (pt)
DE (1) DE60203006T2 (pt)
DK (1) DK1395553T3 (pt)
ES (1) ES2235050T3 (pt)
GB (1) GB0114005D0 (pt)
HK (1) HK1063471A1 (pt)
HU (1) HUP0400156A3 (pt)
IL (1) IL159195A0 (pt)
MX (1) MXPA03011384A (pt)
MY (1) MY136859A (pt)
NO (1) NO326689B1 (pt)
NZ (1) NZ530004A (pt)
PL (1) PL368082A1 (pt)
PT (1) PT1395553E (pt)
SI (1) SI1395553T1 (pt)
TW (1) TWI298719B (pt)
WO (1) WO2002100830A1 (pt)
ZA (1) ZA200309367B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
EP1637141B1 (en) * 2004-09-21 2011-11-16 Trobio AB Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease
WO2006047415A2 (en) * 2004-10-26 2006-05-04 Janssen Pharmaceutica, N.V. Factor xa compounds
WO2006110726A2 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited Dosage formulations and methods of treatment and prevention
CN102380100A (zh) * 2005-09-22 2012-03-21 特罗比奥股份公司 稳定的蛋白酶组合物
JP5080476B2 (ja) * 2005-09-22 2012-11-21 トルービオ・アーベー 安定化プロテアーゼ組成物
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
RU2664538C2 (ru) * 2013-04-26 2018-08-20 Санофи Тартратная соль [(s)-2-[метил-3-(2-оксо-пирролидин-1-ил)-бензолсульфониламино]-3-(4-метил-пиперазин-1-ил)-3-оксо-пропил]амида 5-хлор-тиофен-2-карбоновой кислоты
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4121947A1 (de) 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
WO1998016523A2 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
DE69715658T2 (de) 1996-12-13 2003-05-22 Aventis Pharmaceuticals Inc., Collegeville Sulfonsäure oder sulfonylamino n-(heteroaralkyl)-azaheterocyclylamid verbindungen
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
DK1031563T3 (da) 1997-09-30 2006-05-08 Daiichi Seiyaku Co Sulfonylderivater
KR20010034442A (ko) 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Xa 억제제
CN1298430A (zh) 1998-04-22 2001-06-06 昭和电工株式会社 表面被均匀氟化的粒状金属氧化物及其制造方法和用途
DK1150976T3 (da) 1998-12-31 2003-06-02 Aventis Pharma Inc 3-(Thiosubstituerede amido)lactamer, der er nyttige som inhibitorer af matrixmetalloproteinase
EP1175405A4 (en) 1999-02-09 2002-05-15 Bristol Myers Squibb Co LACTAM INHIBITORS OF FACTOR Xa AND ASSOCIATED METHOD
KR20020004971A (ko) * 1999-03-16 2002-01-16 이경하 치환 프로린 유도체 및 이들을 함유하고 있는 의약 조성물
WO2000069465A1 (fr) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif
CZ2002323A3 (cs) 1999-07-28 2002-05-15 Aventis Pharmaceuticals Products Inc. Substituované oxoazaheterocyklylové sloučeniny a farmaceutické prostředky, které je obsahují
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1395553B1 (en) 2005-02-16
AR036086A1 (es) 2004-08-11
KR20040004706A (ko) 2004-01-13
KR100877245B1 (ko) 2009-01-07
JP4242274B2 (ja) 2009-03-25
US7517879B2 (en) 2009-04-14
ES2235050T3 (es) 2005-07-01
TWI298719B (en) 2008-07-11
BR0210207A (pt) 2004-08-03
CA2449629A1 (en) 2002-12-19
ATE289294T1 (de) 2005-03-15
US7429587B2 (en) 2008-09-30
IL159195A0 (en) 2004-06-01
JP2004537530A (ja) 2004-12-16
AU2002311451B2 (en) 2006-03-02
HUP0400156A2 (hu) 2004-07-28
CZ20033325A3 (cs) 2004-08-18
DE60203006D1 (de) 2005-03-24
US20070142375A1 (en) 2007-06-21
PL368082A1 (en) 2005-03-21
GB0114005D0 (en) 2001-08-01
HK1063471A1 (en) 2004-12-31
MXPA03011384A (es) 2004-04-05
WO2002100830A1 (en) 2002-12-19
US7186717B2 (en) 2007-03-06
EP1395553A1 (en) 2004-03-10
SI1395553T1 (en) 2005-06-30
CO5540285A2 (es) 2005-07-29
NO326689B1 (no) 2009-01-26
ZA200309367B (en) 2004-08-02
DK1395553T3 (da) 2005-06-06
CN1256324C (zh) 2006-05-17
US20050107379A1 (en) 2005-05-19
MY136859A (en) 2008-11-28
DE60203006T2 (de) 2006-03-30
US7326785B2 (en) 2008-02-05
CN1538955A (zh) 2004-10-20
US20070155745A1 (en) 2007-07-05
HUP0400156A3 (en) 2008-10-28
NZ530004A (en) 2005-08-26
NO20035440D0 (no) 2003-12-05
US20070142374A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
AR028576A1 (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
PT1562902E (pt) Derivados de 2-piridona como inibidores da elastase de neutrofilos
AR028575A1 (es) Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
NO20032053D0 (no) Styreskinne
ATE420066T1 (de) Amidoacetonitrilderivate
ATE352550T1 (de) Chinazolinderivate
ATE395345T1 (de) Imidazol-4-yl-ethynyl-pyridin-derivate
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
IS2656B (is) Nýjar besímídasólafleiður
PT1212320E (pt) Fenilpiperazinas como inibidores de reabsorcao de serotonina
PT1395553E (pt) Derivados de pirrolidina como inibidores do factor xa
PT1401828E (pt) Compostos de n-formil-hidroxilamina como inibidores de pdf
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE449064T1 (de) Amidoacetonitrilderivate
DE50308133D1 (de) Ultraschall-stehwellen-zerstäuberanordnung
NO20014234D0 (no) Pyrazol-3-on-derivater som faktor-Xa-inhibitorer